Some thoughts on how the life-sciences sector as a whole can boost productivity, reduce the time to market and unlock the full value of data with AI and machine learning
Kevin Noonan discusses recent developments around researchers vying for ownership of aspects of the gene-editing technology directed to eukaryotic cells
In 2004, California voters passed the California Stem Cell Research and Cures Act to create a foundation for regenerative medicine in the United States at a time when federal funding support declined. No one could have predicted the myriad scientific and medical innovations that have arisen since. This commentary takes a look back at what has happened in those 15 years, as well as to the future of the field
Artificial intelligence is an increasingly important component of the life sciences and pharma/biotech, but let's not lose sight of the fact that it should help, not be designed to lead
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.